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Abstract 
Abdominal Aortic Aneurysm (AAA) is a major cause of mortality and morbidity in men 
over 65 years of age. Male apolipoprotein E knockout (ApoE-/-) mice infused with 
angiotensin II (AngII) develop AAA. Although AngII stimulates both JAK/STAT and Toll-
like receptor 4 (TLR4) signaling pathways, their involvement in AngII mediated AAA 
formation is unclear. Here we used the small molecule STAT3 inhibitor, S3I-201, the 
TLR4 inhibitor Eritoran and ApoE-/-TLR4-/- mice to evaluate the interaction between 
STAT3 and TLR4 signaling in AngII-induced AAA formation. ApoE-/- mice infused for 28 
days with AngII developed AAAs and increased STAT3 activation and TLR4 expression. 
Moreover, AngII increased macrophage infiltration and the ratio of M1 (pro-
inflammatory)/M2 (healing) macrophages in aneurysmal tissue as early as 7-10 days 
after AngII infusion. STAT3 inhibition with S3I-201 decreased the incidence and severity 
of AngII-induced AAA formation and decreased MMP activity and the ratio of M1/M2 
macrophages. Furthermore, AngII-mediated AAA formation, MMP secretion, STAT3 
phosphorylation and the ratio of M1/M2 macrophages were markedly decreased in 
ApoE-/-TLR4-/- mice, and in Eritoran-treated ApoE-/- mice. TLR4 and pSTAT3 levels were 
also increased in human aneurysmal tissue. These data support a role of pSTAT3 in 
TLR4 dependent AAA formation and possible therapeutic roles for TLR4 and/or STAT3 
inhibition in AAA. 
 
Key words:  abdominal aortic aneurysm, toll-like receptor 4, STAT3, angiotensin II 
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1. Introduction 
    Abdominal aortic aneurysm (AAA) affects about 8% of men over the age of 65 years 
in the US, with an annual mortality of more than 15,000.[1-3] Currently, surgical open 
repair and endovascular repair with stenting remain the only treatment for AAA. 
Although several molecular mechanisms have been implicated in the pathogenesis of 
AAA,[4] pathways susceptible to medical therapy that may limit or inhibit aneurysm 
progression have not been validated.  
The development of AAAs in response to Angiotensin II (AngII) in ApoE-/- mice is a 
widely accepted animal model for AAA formation. In this model the early events in 
aneurysm formation involve accumulation of inflammatory cells in the adventitia either 
via recruitment of circulating monocytes or the proliferation of resident macrophages.[5-
7] Macrophages exist in several subsets with distinct functions. M1 macrophages 
mediate pro-inflammatory responses while M2 macrophages exert anti-inflammatory 
effects and regulate wound healing.[8] M1 macrophages release and activate matrix 
metalloproteinases (MMPs) which can degrade extracellular matrix and elastic laminae 
and thus promote dilatation of the lumen and thrombus formation.[5] The combination of 
the inflammatory response, degradation of extracellular matrix constituents including 
elastin, and resulting alterations of blood flow and the development ischemia due to 
thrombus formation result in cellular loss and can promote rupture of the aortic wall.   
The Toll-like receptor (TLR) family of molecular pattern recognition receptors serves 
as cellular sensors for both pathogen-derived and endogenous danger-associated 
molecular patterns. TLR activation results in rapid recruitment of inflammatory cells and 
the local production of pro-inflammatory mediators. TLR4 promotes atherosclerosis in 
mouse models[9, 10] and has recently been implicated in AAA formation.[11]  
The Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) 
pathway  transduces a multitude of signals involved in development, homeostasis and 
inflammation.[12] Ligand binding to receptors activates JAK and STAT proteins which 
are phosphorylated and form homo or heterodimers which then translocate into the 
nucleus where they regulate gene expression.[12] In mammals, the JAK/STAT pathway 
transduces signals for a wide array of cytokines and growth factors including AngII, 
TNF-α, IL-1β, IL-6 and IFN-γ all of which have been implicated in AAA formation.[13-15] 
Stimulation of IL-6 and IL-1 production by bacterial lipopolysaccharide (LPS), a TLR4 
agonist, in a macrophage cell line is decreased after treatment with either a STAT3 
inhibitor or after silencing with a STAT3 siRNA consistent with a role for STAT3 in TLR4 
signaling.[16] The role of the JAK/STAT pathway in TLR4 signaling and AngII-mediated 
AAA formation is, however, unclear. Here we demonstrate that AngII-mediated AAA 
formation potentiates expression of TLR4 and increases the ratio of M1/M2 
macrophages in the abdominal aorta via a STAT3 dependent pathway. Pharmacological 
inhibition of TLR4 or STAT3 markedly attenuates the incidence and severity of AAAs in 
AngII-treated ApoE-/- mice suggesting a role of STAT3 dependent TLR4 signaling in the 
pathogenesis of AAA formation.  
2. Methods 
An expanded Methods section can be found in the supplemental materials. 
2.1 Mice 
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Male ApoE-/- mice on a C57BL/6J background were obtained from The Jackson 
Laboratory (Bar Harbor, ME) and bred in a pathogen-free environment. ApoE-/- and 
TLR4-/- mice were crossbred to obtain ApoE-/-TLR4-/- double knockout mice.[9] Four 
month-old male mice were used for all experiments. All mice were maintained on a 
normal mouse chow diet. Animal care and the experimental procedures were carried 
out in accordance with National Institute of Health guidelines and approved by the Tufts 
Institutional Animal Care and Use Committee. 
2.2 Drug treatment 
Alzet osmotic minipumps (Model 2004, Durect, CA, USA) were implanted into ApoE-/- or 
ApoE-/-TLR4-/- mice to deliver 750 ng/kg/min of AngII (Phoenix Pharmaceuticals, Inc.) 
subcutaneously for 28 days.[5, 17] Placebo, STAT3 inhibitor S3I-201 (5 mg/kg, i.p., 
every other day, Selleckchem) or TLR4 antagonist Eritoran (0.3 mg/kg, i.v., every other 
day, Eisai Inc.) were given for 28 days. S3I-201 inhibits STAT3 phosphorylation with an 
IC50= 86 µM. The dose of S3I-201 was based on the dose of the drug that inhibited 
STAT3 dependent growth of breast tumor cells in mice treated every other day for 15 
days.[18] The dose of Eritoran was based on the daily i.v. bolus required to maintain 
blood levels at 50-100 ng/mL over 2 days and to inhibit the increase in TNFα levels in 
mice treated with LPS.[19]  
2.3 Determination of blood pressure and lipids  
Systolic blood pressures and lipids were measured as described.[17]  
2.4 Classification of aneurysms and measurement of aortic diameter  
The aorta was exposed under a dissecting microscope, and the peri-adventitial tissue 
was removed. Aneurysm severity was rated from Type I to IV according to the method 
of Daugherty et al.[20]: Type I, dilated lumen without thrombus; Type II, remodeled 
aneurysmal tissue with little thrombus; Type III, a pronounced bulbous form of Type II 
with thrombus; Type IV, multiple, often overlapping aneurysms containing thrombus. 
The outer diameter of the suprarenal aorta was measured with a caliper. 
2.5 Tissue harvesting 
After the aorta was exposed, the aneurysmal segment of the aorta was harvested, snap 
frozen in liquid nitrogen, and then stored at -80oC pending further processing for 
western blot and quantitative RT-PCR (qPCR) analysis. Human aneurysmal specimens 
were routinely discarded tissues obtained from patients at the time of AAA repair or 
from normal donors. All specimens were obtained by protocols approved by the Human 
Investigation Review Committee at Brigham and Women’s Hospital.[21]  
2.6 Western Blotting 
Tissue was taken for analysis from the suprarenal aorta and included the aneurysm if 
present. Protein lysates were obtained from the corresponding regions of aneurysmal 
tissue. Western blot analysis was performed as previously described.[17] The Tyr705 
specific pSTAT3 and total STAT3 antibodies were obtained from Cell Signaling 
Technology; the TLR4 and GAPDH antibodies were obtained from Santa Cruz 
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Biotechnology. The protein bands were visualized using chemiluminescent substrates 
(Pierce).  
2.7 Histology 
Perfusion-fixed aortas were embedded in paraffin, cut in cross-section (5~10 μm) and 
stained with hematoxylin and eosin (H&E) and Verhoeff-van Gieson (VVG) for elastin. 
2.8 Gelatin Zymography 
MMP-2 and MMP-9 activities in homogenates of aortic tissue or conditioned media from 
cell cultures were determined by zymography as previously described.[22]  
2.9 Scoring of elastin breaks and aortic wall thickness 
Elastin integrity was graded after VVG staining as described pevioulsy. [23] Wall 
thickness was measured on cross sections from aorta through all three layers of the 
aortic wall: intima, media, and adventitia.[24] 
2.10 Isolation of RNA and quantitative RT-PCR  
RNA was isolated using an RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions. One microgram of RNA sample was then used for reverse transcription and 
synthesis of cDNA using the Superscript III First-Strand system (Invitrogen). 
Quantitative real-time PCR was performed on a Mastercycler ep realplex2 (Eppendorf) 
using SYBR Green PCR Master Mix (Qiagen). GAPDH expression was used as internal 
reference in all PCR experiments. RT-PCR primers (Supplemental Table III) for specific 
target genes were designed based on their reported sequences and synthesized by the 
Tufts University Core Facility. 
2.11 Mouse bone marrow derived macrophages (BMDMs) 
BMDMs were used as an in vitro model for studies of the mechanism of macrophage 
regulation in response to AngII. BMDMs were obtained by flushing the femurs from 
either ApoE-/- or ApoE-/-TLR4-/- mice. Cells were cultured as previously described,[25] 
and BMDMs were treated with AngII (0.25-2 µM) or LPS (10 ng/mL, List Biological 
Laboratories Inc., CA) for 16 hours. The medium was collected for MMP assay, and cell 
lysates for western blot analysis. 
 
2.12 Mouse vascular smooth muscle cells (VSMCs) 
Aortic VSMCs from each of five ApoE-/- or ApoE-/-TLR4-/- mice were obtained by the 
explant method as described previously.[26] Cultured cells were identified as VSMCs by 
immunostaining for smooth muscle-specific α-actin according to the manufacturer’s 
instructions (Sigma Chemical Co.). 
2.13 Flow cytometry analysis  
Aortas were harvested as described and digested following the method of Galkina et 
al.[27] Detailed information can be found in the supplemental materials. Cells were 
filtered, and cell surface staining was performed as previously described[28] using anti-
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CD11b (M1/70, BD Pharmingen), anti-CD11c (HL3, BD Pharmingen), anti-CD206 
(CO68C2 Biolegend), anti-MHC class II (MS114.15.2, eBioscience), anti-F4/80 (BM8 
eBioscience), anti-CD90 (30H12, eBioscience), anti-DX5 (BD Pharmingen), anti-NK1.1 
(BD Pharmingen), anti-B220 (RA3-6B2, BD Pharmingen) and anti-Ly6G (1A8, 
Biolegend). Cellular fluorescence was analyzed using a FacsCanto II cytometer (BD 
Biosciences, San Jose CA), and data were analyzed using FlowJo software (Tree Star, 
Inc. Ashland OR).  
2.14 Statistical analysis 
Data are presented as mean ± SEM. To assess statistical significance, the Kolmogorov-
Smirnov test with Lilliefors’ correction was first employed to determine normal 
distribution. Levene's test was used to test for equality of variances. The student’s t-test 
or Mann-Whitney U test were used for comparison between two groups. Three group’ 
comparisons were carried out using one-way ANOVA (LSD Post-hoc test) or the non-
parametric Kruskal-Wallis test. To assess statistical significance of aneurysm subtype 
variables, cross-tabulated contingency tables were constructed and likelihood ratio Chi-
square statistics, LR were computed. If LRs demonstrated significant differences in the 
aneurysm severity between treatment groups, then Cramer’s V and Goodman and 
Kruskal Tau tests were performed to assess the strength of the association. P<0.05 was 
considered statistically significant. All analyses were performed with IBM SPSS 
Statistics 19.0 (IBM Inc., NY). 
3. Results 
3.1 STAT3 inhibition attenuates the incidence and severity of AngII-induced AAA 
formation  
To test the hypothesis that the JAK/STAT pathway participates in AngII-induced AAA 
formation in ApoE-/- mice, the level of pSTAT3 in abdominal aortas of AngII and 
placebo-treated ApoE-/- mice was compared. AngII treatment resulted in a 2.18±0.12 
fold increase (n=4, p<0.01) in the phosphorylation of STAT3 at Tyr705, while total 
STAT3 (tSTAT3) levels increased by 1.60±0.12 fold (p<0.05, Figure 1A and 1B). The 
increase in total STAT3 in association with increased pSTAT3 is consistent with data 
demonstrating regulation of STAT3 expression by pSTAT3 dimers.[29] Most 
importantly, the ratio of pSTAT3/tSTAT3 increased by 1.57±0.06 fold (n=4, p<0.01). The 
small molecule STAT3 inhibitor S3I-201 binds with high specificity to the SH2 domain of 
STAT3, interfering with dimerization and DNA binding.[18] To determine whether the 
increase in pSTAT3 contributed to the pathogenesis of AngII-induced AAA formation, 
ApoE-/- mice were treated with either S3I-201 or vehicle. Continuous infusion with S3I-
201 significantly reduced the incidence of AAA formation from 84% in the placebo-
treated group (n=19) to 40% in the S3I-201 treated group (n=15, p<0.05) (Fig. 1C). 
Based on the classification system of Daugherty et al.[20] S3I-201 also decreased the 
severity of the aneurysms (Fig. 1D, supplemental Fig. S1 and supplemental Table I). 
The distribution of aneurysms was significantly different between the 2 treatment groups 
as determined by the Likelihood Ratio ᵡ2 test (p=0.009), the Goodman and Kruskal Tau 
test, and the Cramer’s V test, p<0.05 for each (Supplemental Table I). Furthermore, the 
maximal external diameter of the aorta was also significantly decreased from 
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1.84±0.14mm in placebo-treated mice (n=19) to 1.16±0.07mm in the S3I-201 treated 
group (n=15, p<0.01) (Fig. 1E). Western blot analysis confirmed that treatment of mice 
with S3I-201 decreased the ratio of pSTAT3/tSTAT3 in AngII-induced aneurysms from 
3.65±0.28 (n=4) to 1.16±0.11 (n=4, p<0.01) fold increase vs. normal aorta (Fig. 1F, G). 
S3I-201 had no effect on body weight, plasma cholesterol concentration or systolic 
blood pressure (Supplemental Table II). 
3.2 STAT3 inhibition attenuates aortic wall remodeling, elastin degradation and 
suppresses macrophage infiltration and MMP activity in AngII treated ApoE-/- mice.   
H&E staining of cross sections taken from the suprarenal region of the aorta 
demonstrated that AngII treatment resulted in a marked thickening of the abdominal 
aortic wall. Both the maximal wall thickness and the minimal wall thickness were 
markedly increased in AngII treated mice, while S3I-201 treatment reduced both 
maximum and minimum wall thicknesses (Table I, Fig. 2A). Furthermore, treatment with 
S3I-201 significantly decreased elastin degradation in AAA lesions of AngII-infused 
ApoE-/- mice from grade 1.54 ± 0.09, n=18 to grade 0.99 ± 0.10, (n=16, p<0.01) 
respectively (Fig. 2A and B), where Elastin integrity of VVG stained sections was 
graded  as: grade 0, no interruption in the medial elastic laminae; grade 1, noticeable 
interruption in the medial elastic laminae without change of luminal shape; grade 2, 
prolonged disruption in the elastic laminae with bulbous extension of the aortic lumen.  
Table I 
Elastin score and wall thickness in ApoE-/- mice treated with AngII, S3I-201, and in AngII treated 
ApoE-/-TLR4-/- mice 
 
ApoE-/- ApoE-/-TLR4-/- 
 
Control 
(n=6) 
AngII  
(n=12) 
AngII+S3I-201 
(n=12) 
AngII  
(n=6) 
Elastin score N.A 1.540±0.090 0.990±0.100# 1.075±0.025# 
Wall thickness 
(Maximal, mm) 
0.073±0.017 1.315±0.1698** 0.271±0.109## 0.390±0.076## 
Wall thickness 
(Minimal, mm) 
0.004±0.004 0.219±0.078** 0.037±0.021## 0.074±0.045## 
All results are expressed as mean±SEM. **P<0.01 compared with control, #P<0.05 and 
##P<0.01 compared with AngII group. 
In order to determine the role of STAT3 in macrophage infiltration of aneurysmal tissues, 
CD11b+Lin-F4/80+ cells were measured by flow cytometry. As shown in Fig. 2C, AngII 
infusion promoted macrophage infiltration by 19.75±1.65-fold (n=5, p<0.01 vs. control 
group), and treatment with S3I-201 decreased macrophage infiltration to 9.59±2.58-fold 
(n=5, p<0.01 vs. the AngII group). These data are consistent with the well-established 
role of macrophages in the development of AAAs. Although the source of macrophages 
in aneurysmal tissue is unclear[2], BMDMs were used as an in vitro model to study the 
direct effects of AngII on a specific cell type found in the aneurysm. Stimulation with 
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AngII increased pSTAT3 levels in BMDMs from ApoE-/- mice in a dose-dependent 
manner with a 1.38±0.05 fold (n=3) increase at 0.25 µM, and a maximal effect of 
3.23±0.15 fold (n=3, p<0.05) at 0.5 µM (Supplemental Fig. S2). 
MMPs contribute to the initiation and progression of AAA formation,[30] particularly 
MMP2 and MMP9 which were increased in the abdominal aortas of AngII-treated ApoE-
/- mice.[17, 31, 32] To determine whether AngII stimulation of MMP secretion was 
dependent on pSTAT3, the effect of S3I-201 on MMP2 and MMP9 activity in suprarenal 
aortas of AngII-treated ApoE-/- mice was measured. S3I-201 treatment significantly 
down-regulated MMP9 activity (9.50±0.65 vs. 1.73±0.31 fold in AngII and AngII+S3I-201 
treated mice, respectively), and MMP2 activity (5.10±0.28 vs. 1.73±0.14 fold, n=4, 
p<0.01) (Fig. 2D and E).     
Vascular smooth muscle cells are a major component of the aortic wall and have 
been implicated in synthesis of extracellular matrix, protease activity and recruitment of 
inflammatory cells.[33] To further establish the role of STAT3 in AAA formation, we used 
VSMCs as a second in vitro model to study the role of pSTAT3 in the pathogenesis of 
AAAs.  VSMCs were starved in DMEM for 8 hours followed by treatment with 0.5µM 
AngII for 16 hours. S3I-201 (100 µM ) or vehicle was added 1 hour prior to AngII. Cells 
were harvested for western blot analysis and medium for zymographic 
analysis.  pSTAT3 levels increased 1.89±0.08 fold, while MMP2 levels increased 
1.69±0.12 fold (n=4, P< 0.05), while treatment with S3I-201 completely reversed this 
effect (Supplementary Fig. S3).    
3.3 The ratio of M1/M2 macrophages is increased in AngII-induced AAA formation 
and STAT3 inhibition markedly reverses M1 polarization  
At least 2 subsets of macrophages have been described based on functional phenotype. 
Pro-inflammatory M1 macrophages are characterized by the cell surface marker CD11c, 
high surface expression of MHC class II and the intracellular marker iNOS. “Healing” M2 
macrophages are characterized by the cell surface marker CD206 and intracellular 
marker Ym-1. Flow cytometry analysis based on the cell surface markers was used to 
determine the M1 and M2 subtypes (Supplemental Fig. S4). Since no combination of 
cell surface markers is able to unequivocally identify M1/M2 macrophages, qPCR 
analysis for expression of iNOS and Ym-1 was further used to validate flow cytometry 
data.  
    In order to determine whether macrophage infiltration and macrophage phenotype 
play a role in the early events of AAA formation, the suprarenal aortas from ApoE-/- mice 
7-10 days after AngII treatment were used for flow cytometry. At this time point only 2 
out of 16 mice (13%) developed AAAs. Flow cytometric analysis of the suprarenal 
aortas from 6 of these mice with no visible evidence of AAAs demonstrated a 2.91±0.45 
fold increase (n=6, p<0.01) in total macrophages compared to control as determined by 
CD11b+Lin-F4/80+ cells (Fig. 3A). Importantly, the ratio of M1/M2 was significantly 
increased by 3.07±0.82 fold (n=6, p<0.05, Fig. 3A). These data supported the 
conclusion that macrophage accumulation and an increase in the ratio of M1/M2 
phenotype are early pro-inflammatory events in AAA formation. Furthermore, after 28 
days of AngII treatment, total macrophages increased 19.75±1.65 fold compared to 
control (Fig. 2C), while the ratio of M1/M2 macrophages increased 5.87±0.73 fold (n=4, 
p<0.01, Fig. 3B and C). Importantly, S3I-201 treatment not only markedly decreased 
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total macrophage infiltration (Fig. 2C) but also significantly decreased the ratio of M1/M2 
macrophages to 2.93±0.34 fold (n=5, p<0.01) above control (Fig. 3B and C). These 
findings were further supported by qPCR analysis of mRNA levels of iNOS, an M1 
marker and Ym-1, an M2 marker. AngII infusion increased iNOS mRNA expression in 
aneurysmal tissue 66.87±5.80 fold (n=4, p<0.01) above the control, while treatment with 
S3I-201 decreased iNOS mRNA level to 12.76±3.58 fold above control (n=4, p<0.01). 
Conversely, AngII infusion decreased Ym-1 mRNA to 0.44±0.11 fold (n=4, p<0.01), 
while S3I-201 treatment increased Ym-1 to 1.24±0.32 fold (n=4, p<0.01). Additionally 
the ratio of iNOS/Ym-1 increased 145.44±22.42 fold (n=4, p<0.01) in response to AngII, 
but increased to only 9.65±3.51 (n=4, p<0.01) in response to AngII plus S3I-201 
treatment (Fig. 3D). These data supported the conclusion that the AngII mediated 
increase in pro-inflammatory macrophages in the suprarenal aortas of ApoE-/- mice was 
dependent at least in part on pSTAT3.  
3.4 AngII up-regulates the expression of TLR4  
Recent evidence supports a role of TLR4 signaling in the pathogenesis of AngII-induced 
aortic aneurysms in LDLR-/- mice.[11] To further investigate the role of TLR4 in AngII-
induced AAA formation, we determined whether TLR4 expression was increased in 
aneurysms in these mice. TLR4 mRNA level determined by qPCR were 4.76±0.72 fold 
higher (n=5, p<0.01) in the suprarenal aorta of AngII treated mice compared with control 
(Fig. 4A). Furthermore, western blot analysis demonstrated that TLR4 protein level was 
also increased 1.78±0.15 fold (n=4, p<0.05) in AngII-treated mice compared to control 
(Fig. 4B and C). To validate this effect of AngII on macrophages in vitro, we determined 
the effect of AngII on TLR4 levels in BMDMs. Data outlined in Supplemental Fig. S5 
demonstrate that AngII increased TLR4 protein expression in BMDMs from ApoE-/- mice 
in a dose-dependent manner.  
3.5 TLR4 deficiency attenuates AngII-induced pSTAT3  
AngII mediated AAA formation had been shown to be dependent on TLR4[11]. Here we 
determined whether AngII mediated activation of STAT3 was also dependent on TLR4. 
We determined the effect of AngII treatment on AAA formation in an ApoE-/-TLR4-/- 
mouse. The incidence and severity of AAA formation were both significantly reduced in 
ApoE-/-TLR4-/- mice compared to the ApoE-/- controls (Fig. 4D and E). AAA incidence 
decreased from 80% in ApoE-/- mice (n=20) to 39% in ApoE-/-TLR4-/- mice (n=18, 
p<0.05). AAA severity also decreased in AngII treated ApoE-/-TLR4-/- mice compared 
with ApoE-/- mice: 65% of ApoE-/- mice treated with AngII developed either type III or 
type IV aneurysms compared with 17% of ApoE-/-TLR4-/- mice (Fig. 4E, Supplemental 
Table I). The distribution of aneurysms was significantly different between the 2 
treatment groups as determined by the Likelihood Ratio ᵡ2 test (p=0.002), the 
Goodman and Kruskal Tau test, and the Cramer’s V test, p<0.007 for each 
(Supplemental Table I). In addition, the maximal aortic diameter decreased from 
1.89±0.18mm (n=20) in ApoE-/- mice to 1.26±0.20mm (n=18, p<0.05) in ApoE-/-TLR4-/- 
mice (Fig. 4F). Furthermore, the elastin score decreased significantly in the suprarenal 
aorta of the AngII treated ApoE-/-TLR4-/- mouse compared to the AngII treated ApoE-/- 
mice (Table I, Supplemental Fig. S6). Similarly, both maximal and minimal aortic wall 
thickness were significantly decreased in the ApoE-/-TLR4-/- mice compared with the 
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ApoE-/- (Table I, Supplemental Fig. S6) consistent with a marked decrease in aneurysm 
severity. Additionally, TLR4 deficiency resulted in a significant down-regulation of AngII 
stimulated MMP9 and MMP2 activity (Fig. 5A, B). Systolic blood pressure, serum 
cholesterol level and body weight did not differ significantly between ApoE-/- and ApoE-/-
TLR4-/- mice (Supplemental Table II).  
   Finally to determine whether the increase in pSTAT3 found in AngII-induced 
aneurysms is dependent on TLR4 signaling, we compared levels of STAT3 
phosphorylation in homogenates of the suprarenal aortas from AngII-treated ApoE-/- and 
ApoE-/-TLR4-/- mice. Knockout of TLR4 resulted in a decrease in AngII-mediated 
pSTAT3 from 2.64±0.15 fold above control to 1.56±0.30 fold (n=4, p<0.01, Fig. 5C and 
D) consistent with a role of TLR4 in pSTAT3-mediated AAA formation. The link between 
TLR4 and AngII-induced pSTAT3 is further supported by the finding that treatment of 
BMDMs from ApoE-/- mice with either AngII or LPS increased pSTAT3 levels, by 
6.41±2.48 fold (n=3, p<0.05) and 12.17±1.99 fold (n=3, p<0.05) respectively. Neither 
AngII nor LPS had an effect on pSTAT3 in BMDMs from ApoE-/-TLR4-/- (Fig. 5E and F).  
The role of TLR4 in AAA formation is further supported by the finding that AngII 
mediated STAT3 activation and MMP2 secretion in VSMCs cultured from ApoE-/- mice, 
was abolished by TLR4 deficiency (Fig. S7).   
3.6 TLR4 deficiency attenuates the AngII-induced increase in M1/M2 ratio  
To determine whether the AngII-induced increase in M1 macrophages and M1/M2 ratio 
were dependent on TLR4 signaling, the effect of AngII on macrophage phenotypes in 
the suprarenal aortas of ApoE-/-TLR4-/- mice was determined by qPCR analysis. TLR4 
deficiency in AngII treated mice decreased iNOS expression from 47.20±21.21 fold 
above control (n=4, p<0.01) in ApoE-/- mice to 5.76±0.53 fold (n=4, p<0.01) above 
control in ApoE-/-TLR4-/- mice consistent with a marked decrease in M1 phenotype in the 
TLR4-/- mouse. Conversely, compared to control, TLR4 deficiency in AngII treated mice 
increased Ym-1 expression from 0.75±0.19 fold (n=4, p<0.05) in ApoE-/- mice to 
2.85±0.66 fold (n=4, p<0.01) in ApoE-/-TLR4-/- mice consistent with an increase in the 
M2 phenotype. Additionally the ratio of iNOS/Ym-1 in AngII-treated mice decreased 
from 85.27±50.48 fold (n=4, p<0.05) above control in ApoE-/- mice to 2.12±0.59 (n=4, 
p<0.05, Fig. 5E) in ApoE-/-TLR4-/- mice. 
3.7 Eritoran, a small molecule TLR4 Inhibitor, attenuates AngII-induced AAA 
formation, STAT3 stimulation, MMP activity and M1/M2 ratio  
Given data supporting a role of TLR4 in AngII-induced AAA formation,[11] we 
determined whether TLR4 inhibitors might have therapeutic potential in the treatment of 
AAAs. A number of small molecule TLR4 inhibitors have been developed for the 
treatment of sepsis, including Eritoran (Eisai, Inc.).[34] To determine the effect of 
pharmacologic inhibition of TLR4 on aneurysm formation, ApoE-/- mice receiving 
continuous AngII infusion were treated with either placebo or Eritoran (300 µg/kg, i.v.) 
every other day. Eritoran treatment decreased the incidence of AAA formation from 80% 
to 44% (n=10 and 9 respectively, Fig. 6A). AAA severity also decreased in Eritoran 
treated mice compared with placebo treated: 60% of placebo-treated mice developed 
either type III or type IV aneurysms compared with 33% of mice that developed type III 
aneurysms while no type IV aneurysms were found in Eritoran-treated mice. Eritoran 
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treatment also significantly reduced maximal aortic diameter from 1.91±0.18 mm (n=10) 
to 1.35±0.19 mm (n=9, p<0.05) (Fig. 6B). Eritoran had no effect on body weight, plasma 
cholesterol and systolic blood pressure (Supplemental Table II). 
    Additionally, Eritoran treatment significantly down-regulated AngII-stimulated MMP9 
activity from 16.39±1.64 to 1.62±0.30 fold and MMP2 activity from 7.80±0.43 to 
2.19±0.76 fold respectively above those in control mice (n=4, p<0.01, Fig. 6C and D). 
Furthermore, Eritoran significantly attenuated AngII-stimulated pSTAT3 levels from 
3.08±0.56 fold to 1.76±0.36 fold compared with control (n=4, p<0.05) (Fig. 6E and F) 
and inhibited the AngII-mediated increase in M1/M2 ratio. The mRNA level of iNOS 
significantly decreased from 39.65±8.10 to 8.49±0.54 fold (n=4, p<0.01), while the 
mRNA level of Ym-1 increased from 0.48±0.12 to 1.23±0.34 fold (n=4, p<0.05) in 
Eritoran treated mice.  Finally, the ratio of iNOS/Ym-1 decreased from 105.21±40.94 to 
7.20±1.45 fold (n=4, p<0.01) by Eritoran (Fig. 6G).  
3.8 Increased TLR4 expression and STAT3 activation in human AAAs 
In order to test the potential clinical relevance of our findings, the levels of TLR4 and 
pSTAT3 in human AAA tissue were measured. Aortic aneurysmal tissue taken from 
AAA patients at the time of open surgical repair demonstrated significantly higher levels 
of TLR4, pSTAT3 and tSTAT3 1.99±0.25, 2.04±0.08 and 1.22±0.02 fold respectively, 
compared to aortic tissue from normal donors without AAA (n=4, p<0.05, Fig. 7A and B). 
4. Discussion 
These data support the conclusion that the incidence and severity of AngII-induced AAA 
formation in ApoE-/- mice depends at least in part on the AngII-mediated activation of 
STAT3. Furthermore, the finding that both AngII-mediated AAA formation and STAT3 
phosphorylation are markedly attenuated in ApoE-/-TLR4-/- mice and in ApoE-/- mice 
treated with the TLR4 inhibitor Eritoran strongly supports the conclusion that AngII 
stimulates STAT3, by mechanisms that involve TLR4 signaling (Fig. 7C). The finding 
that AngII markedly increased macrophage infiltration in the suprarenal aorta with a 
predominant increase in the ratio of pro-inflammatory M1 macrophages to anti-
inflammatory/healing M2 macrophages at an early time point (7-10 days after AngII 
infusion) when there is little anatomical evidence of AAA formation, is consistent with 
the conclusion that macrophage infiltration is an early event in AAA formation, and that 
M1 macrophages may play an early role in the pathogenesis of AAAs in this model. 
After 28 days of AngII infusion, at a time when 84% of animals develop AAA, we 
observe a further increase in both the extent of macrophage infiltration and an increase 
in the ratio of M1/M2 macrophages. Importantly the increase in the M1/M2 ratio at day 
28 was reversed by inhibition of either STAT3 or TLR4 signaling. The observed 
increase in M1/M2 macrophages may be due to proliferation of resident macrophages 
or macrophage differentiation of circulating monocytes after infiltration of the aortic wall. 
Furthermore, recent data suggest that everolimus, an mTOR inhibitor, attenuated M1 
polarization in ApoE-/- BMDMs in vitro and AAA formation in vivo.[35] The choice of 
BMDM as an in vitro model for changes observed in the intact suprarenal aorta is 
complicated by a recent bone marrow transplant study in which donor marrow from 
cholesterol fed LDLR-/-TLR4-/- mice had no effect on the increase in aortic diameter in 
cholesterol fed LDLR-/- recipient mice treated with high doses of AngII.[11] However, 
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given that increased levels of macrophages is well established in the pathogenesis of 
AAA, whether these cells migrated from the spleen, the bone marrow or represent 
proliferation of resident macrophages, does not preclude the use of BMDM as an in vitro 
model for studies of the mechanism of macrophages regulation in response to AngII. 
Using BMDM, we determined that the levels of pSTAT3 and TLR4 were dose 
dependently increased in response to AngII. Given the preponderance of VSMCs in the 
wall of the aorta and data supporting a role of VSMCs in AAA formation[33], we used 
VSMCs as second in vitro model.  Data demonstrated that increased pSTAT3 and MMP 
secretion in VSMCs in response to AngII which was dependent on TLR4 signaling 
further supporting the validity of the conclusions derived from homogenates of the 
suprarenal aortas.   
    The role of TLR4 in the pathogenesis of AAAs is supported by recent data 
demonstrating a decreased incidence of AAA formation in cholesterol fed LDLR-/- TLR4-
/- mice treated with AngII.[11] Here we demonstrate that the incidence and severity of 
AAA formation were markedly decreased in AngII-treated ApoE-/- that were TLR4-
deficient, or were treated with a small molecule TLR4 inhibitor. Furthermore the finding 
that stimulation of STAT3 phosphorylation in response to both AngII and LPS was 
markedly attenuated in BMDM from ApoE-/-TLR4-/- mice further support the role of TLR4 
in STAT3 mediated AAA formation. The finding that TLR4 expression is increased in the 
suprarenal aorta of AngII treated ApoE-/- mice and that AngII dose dependently 
increased TLR4 expression in BMDM from ApoE-/- mice is consistent with a potentiation 
of TLR4 signaling in response to AngII. Recently, Greenhill et al. demonstrated that 
mice with hyper-expression of the IL6 cytokine receptor subunit gp130 are hyper-
responsive to the TLR4 ligand LPS.[36] This effect was significantly attenuated in 
STAT3-/- gp130 overexpressing mice indicating a role of STAT3 in TLR4 signaling. 
However, in another study, STAT3 knockdown potentiated TLR4 dependent 
ischemia/reperfusion injury in mouse liver.[37] These data suggest pleiotropic effects of 
STAT3 potentiating or attenuating TLR4 signaling in different disease models. 
Importantly, treatment of ApoE-/- mice with Eritoran not only significantly decreased the 
incidence and severity of AAAs, but also interfered with AngII-mediated secretion of 
MMPs and the accumulation of M1 macrophages in the suprarenal aortas of ApoE-/- 
mice consistent with a potential therapeutic role for TLR4 inhibitors in the treatment of 
AAAs.        
    Although the role of the JAK/STAT pathway in AngII signaling is supported by studies 
which demonstrate the binding of JAK2 to angiotensin receptor 1 and the activation of 
STAT1 and STAT2 in vascular smooth muscle cells[13] and the activation of STAT3 in 
rat cardiomyocytes,[38] its role in the pathogenesis of AAAs is unclear. Our data 
demonstrate a role for AngII in the activation of STAT3 in the pathogenesis of AAAs. 
Specifically, S3I-201, a small molecule inhibitor with a high degree of specificity for 
STAT3, which interferes with dimerization of STAT3,[18] markedly decreased both the 
incidence and severity of AAAs, MMP secretion, macrophage infiltration and M1/M2 
ratio in an AngII-induced ApoE-/- mouse model. Recent data demonstrating the 
association of a variant of the IL-6 receptor with decreased incidence of AAAs and 
decreased expression of STAT3,[39] further suggested a role of STAT3 in AAA 
formation. Furthermore, in a recent study aged C57BL/6 mice treated with very high 
doses of AngII (2500 ng/kg) developed aortic dilatation that was attenuated by a STAT3 
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inhibitor peptide.[40] Consistent with these findings, our data demonstrated a marked 
elevation of pSTAT3 and total STAT3, as well as TLR4 in tissue samples obtained from 
patients during AAA repair compared with levels in non-aneurysmal aortic tissue from 
organ donors. These data are consistent with the findings of a recent study 
demonstrating increased pSTAT3 in patients with AAAs.[41] Interestingly, in a different 
model of AngII mediated AAA formation in which C57BL/6 wild-type mice were treated 
with neutralization antibody to TGFβ, selective deletion of STAT3 in macrophages and 
neutrophils did not affect aneurysm development.[42] These differences likely reflect 
differences in the mechanisms of TGFβ effects on AAA formation 
    Our study demonstrates roles of both STAT3 and TLR4 signaling in AngII-mediated 
AAA formation. The role of STAT3 in the pathogenesis of AAAs is further supported by 
data demonstrating that STAT3 activation is necessary for AngII-stimulated MMP 
secretion and the increase in total macrophages and the ratio of MI/M2 macrophages in 
suprarenal aortas of ApoE-/- mice. The findings that inhibition of TLR4 signaling by 
Eritoran and inhibition of STAT3 signaling by S3I-201 significantly decreased the 
incidence and severity of AAA formation in this mouse model suggest that both TLR4 
and STAT3 might serve as therapeutic targets in the treatment of AAAs.   
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Figure Legends 
 
Figure 1 The STAT3 inhibitor, S3I-201, decreases the incidence and severity of AAA 
formation. (A) Effect of AngII on pSTAT3 and tSTAT3 in aneurysmal tissues determined 
by western blotting. (B) Densitometric analysis of data in A normalized to GAPDH 
(*p<0.05, **p<0.01 vs. control, n=4 per group). (C) S3I-201 significantly reduced the 
incidence of AAA formation from 84% (AngII) to 40% (p<0.05, n=19 and 15), (D) S3I-
201 significantly reduced the severity of AAA based on the classification of aneurysms. 
(E) The external diameter of the aorta was also significantly decreased by S3I-201 
treatment (##p<0.01 vs. placebo, n=19 and 15), (F & G) S3I-201 decreased AngII-
induced pSTAT3/tSTAT3 determined by western blot (**p<0.01 vs. control, ##p<0.01 vs. 
placebo, n=4).  
Figure 2 S3I-201 attenuates AngII-induced remodeling of the aortic wall, macrophage 
infiltration and MMP activity in the abdominal aortas. (A) Representative 
photomicrographs of aortic cross sections. Top, H&E staining, bottom, VVG elastin 
staining. (B) Area defined by the square in A demonstrating the elastin degradation. (C) 
S3I-201 significantly decreased the total macrophage (CD11b+Lin-F4/80+) infiltration in 
the abdominal aortas measured by flow cytometry. (D & E) S3I-201 significantly 
decreased AngII-induced gelatinolytic activities of MMP2 and MMP9 in homogenates of 
the aortas determined by gelatin zymography (**p<0.01 vs. control ##p<0.01 vs. placebo, 
n=4).  
Figure 3 The role of M1/M2 macrophages in AngII-induced AAA formation. (A) Total 
macrophage and M1/M2 ratio measured by flow cytometry were increased at day 7-10 
after AngII treatment (n=6, *p<0.05, **p<0.01 vs. control). (B) The ratio of M1/M2 was 
further increased by AngII treatment at day 28, while S3I-201 markedly decreased 
M1/M2 ratio (n=5, **p<0.01 vs. control, ##p<0.01 vs. placebo). (C) Representative plots 
illustrating identification of M1 macrophage (CD11c+), and M2 macrophage (CD206+) in 
aortic digests. (D) The effects of AngII and S3I-201 on the expression of iNOS, Ym-1 
mRNA and the ratio of iNOS/Ym-1 (n=4, **p<0.01 vs. control, ##p<0.01 vs. placebo).  
Figure 4 Role of TLR4 in AngII-induced AAA formation in ApoE-/- mice. (A) AngII 
increased the mRNA level of TLR4 in suprarenal aorta determined by qPCR (**p<0.01 
vs. control, n=4). (B & C) AngII increased TLR4 protein level determined by western blot 
analysis (*p<0.05 vs. control, n=4). (D and E) Deficiency of TLR4 significantly reduced 
the incidence and severity of AAA formation in ApoE-/- mice (p<0.05, n=18 and 20 per 
group). (F) The maximal aortic diameter was also significantly decreased by TLR4 
deficiency (*p<0.05 vs. control, n=18 and 20 per group, respectively).  
Figure 5 TLR4 knockout attenuates AngII-induced pSTAT3 and the ratio of M1/M2. 
(A & B) TLR4 deficiency decreased AngII-induced pSTAT3 in aortic homogenates 
(***p<0.001 vs. control, ##p<0.01 vs. ApoE-/-+AngII, n=4). (C & D) TLR4 deficiency 
attenuated AngII- and LPS- induced activation of pSTAT3 in BMDMs from ApoE-/- mice 
determined by western blot analysis (**p<0.01 vs. control, n=4). (E) The effect of TLR4 
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deficiency on iNOS, Ym-1 and the ratio of iNOS/Ym-1 mRNA levels (n=4, *p<0.05 vs. 
control, **p<0.01 vs. control, ##p<0.01 vs. ApoE-/-+AngII). 
Figure 6 The TLR4 inhibitor Eritoran decreases the incidence of AngII-induced AAAs, 
the activation of STAT3 and M1/M2 ratio. (A & B) Eritoran significantly reduced the 
incidence of AngII-induced AAA formation and the external diameter of the aortas 
(*p<0.05 vs. placebo, n=9 and 10 per group). (C & D) Eritoran decreased the 
gelatinolytic activities MMP2 and MMP9 in AngII-treated ApoE-/- mice measured by 
zymography in homogenates of aortas (**p<0.01 vs. control, ##p<0.01 vs. placebo, n=4). 
(E & F) The activation of STAT3 induced by AngII was significantly decreased by 
Eritoran, as determined by western blot analysis of homogenates of aortas (*p<0.05 vs. 
control, #p<0.05 vs. placebo, n=4). (G) The effect of Eritoran on iNOS, Ym-1 and the 
ratio of iNOS/Ym-1 mRNA levels, as measured by qPCR (n=4, *p<0.05, vs. control, 
**p<0.01 vs. control, ##p<0.01 vs. placebo). 
Figure 7 Abdominal aortas from patients with AAA demonstrate increased levels of 
TLR4, pSTAT3 and tSTAT3 compared to normal donor aortas. (A & B) Western blot 
analysis of TLR4, pSTAT3, tSTAT3 in tissue homogenates of aortic tissue taken at the 
time of aneurysmal repair and aortas from normal organ donors (*p<0.05 vs. control, 
n=4). (C) Schematic representation of proposed pathway for the link between STAT3 
and TLR4 in AngII-induced of AAA formation.  
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Expanded Methods 
2.3 Determination of blood pressure and lipids  
Systolic blood pressures were measured in trained, prewarmed conscious mice by 
using a tail cuff apparatus coupled to a PC-based data acquisition system (Kent 
Scientific Corporation). To avoid procedure-induced anxiety, mice were initially 
acclimated to the instrument for 3 consecutive days before the actual measurement. On 
the fourth day, pressures were measured in both the morning and afternoon. Moreover 
the first 5 of 30 blood pressure values at each session were disregarded, and the 
remaining 25 values were averaged and used for analysis.1 Plasma samples were 
obtained from individual mice at the time of sacrifice for analysis of cholesterol 
enzymatically (IDEXX Laboratories).  
2.8 Gelatin Zymography 
MMP-2 and MMP-9 activities in homogenates of aortic tissue or conditioned media from 
cell cultures were determined by zymography as previously described.2 Briefly, gelatin 
zymography was performed under non-reducing conditions on SDS-PAGE gels 
containing 1 mg/ml porcine gelatin. Gel electrophoresis was performed at 150 V for 1 
hour. After electrophoresis, the gel was washed in 2.5% Triton X-100 solution with 
gentle agitation for 6 hours at room temperature, followed by replacement with 
developing buffer containing 50 mM Tris-HCl (pH 7.5), 0.2 M NaCl, 5 mM CaCl2 and 0.2% 
Brij-35). The gel was agitated at room temperature for 30 min, placed in fresh 
developing buffer, and incubated at 37 ºC overnight. The following morning, gels were 
stained with 0.5% Coomassie brilliant Blue R-250 in 40% methanol and 10% acetic acid 
for 2-4 hours and destained in 40% methanol and 10% acetic acid at room temperature. 
Gelatinolytic bands were quantified by scanning densitometry with NIH ImageJ software.  
 
2.11 Mouse bone marrow derived macrophages (BMDMs) 
Macrophages have been found abundant in aneurysmal tissue, though the source of 
macrophages infiltrating the abdominal aorta in the pathogenesis of AAAs is unclear. 
BMDMs were used as an in vitro model for studies of the mechanism of macrophage 
regulation in response to AngII. BMDMs were obtained by flushing the femurs from 
either ApoE-/- or ApoE-/-TLR4-/- mice. Cells were cultured as previously described in 
DMEM containing 10% heat inactivated FBS and L929-cell conditioned medium at a 
final concentration of 30% (v/v) as a source of granulocyte/macrophage colony 
stimulating factor which drive the bone marrow monocyte/macrophage progenitors to 
proliferate towards a greater than 95% pure population of macrophages.3 At Day 7-8, 
BMDMs were trypsinized, plated in experimental culture dishes and incubated overnight. 
Next day, cells were starved in DMEM for 8 hours, and then treated with AngII (0.25-2 
µM) or LPS (10 ng/mL, List Biological Laboratories Inc., CA) for 16 hours. The medium 
was collected for MMP assay, and cell lysates for western blot analysis. 
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2.13 Flow cytometry (FACS) analysis  
Aortas were harvested as described and digested following the method of Galkina et 
al.4 Briefly, aortas were minced in 2ml digestion buffer (125 U/ml Collagenase type XI, 
60 U/ml Hyaluronidase type 1-s, 60 U/ml DNase I, and 450 U/ml Collagenase type I, in 
PBS) and incubated at 37oC for one hour with shaking. Cells were filtered, and cell 
surface staining was performed as previously described5 using anti-CD11b (M1/70, BD 
Pharmingen), anti-CD11c HL3, (BD Pharmingen), anti-CD206 (CO68C2 Biolegend), 
anti-MHC class II (MS114.15.2, eBioscience), anti-F4/80 (BM8 eBioscience), anti-CD90 
(30H12, eBioscience), anti-DX5 (BD Pharmingen), anti-NK1.1 (BD Pharmingen), anti-
B220 (RA3-6B2, BD Pharmingen) and anti-Ly6G (1A8, Biolegend). All cytometry was 
performed on a FacsCanto II cytometer (BD Biosciences, San Jose CA), and data were 
analyzed using FlowJo software (Tree Star, Inc. Ashland OR).  
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Supplemental Table I 
Crosstabulation Table used for Statistical Analysis of Aneurysm Severity by Treatment                             
Treatment Aneurysm Type  
 none Type I Type II Type III Type IV total 
AngII+Placebo Count 3 0 3 8 5 19 
% 16 0 16 42 26 100 
AngII+S3I-201 
Count 9 1 3 2 0 15 
% 60 7 20 13 0 100 
                                                                          LR†             Tau‡                      V†† 
*AngII+Placebo vs. AngII+S3I-201    13.545 (P=0.009)      0.328 (P=0.029)         0.573 (P=0.025) 
†Likelihood Ratio, ‡Goodman and Kruskal Tau, ††Cramer’s V 
Genotype Aneurysm Type  
 none Type I Type II Type III Type IV total 
ApoE-/- Count 4 0 3 9 4 20 
% 20 0 15 45 20 100 
ApoE-/-TLR4-/- 
Count 11 3 1 3 0 18 
% 60 17 6 17 0 100 
                                                                  LR†   Tau‡                  V†† 
*ApoE-/- vs. ApoE-/-TLR4-/-        7.182 (P=0.002)          0.374 (P=0.008)           0.611(P=0.007) 
   
 
  
Supplemental Table II 
Systolic blood pressure and total cholesterol in ApoE-/- mice treated with Ang II, S3I-201 
and Eritoran, and in Ang II treated ApoE-/-TLR4-/- mice 
ApoE-/- ApoE-/-TLR4-/- 
 
Control 
(n=10) 
AngII 
(n=10) 
AngII+S3I-201 
(n=7) 
AngII+Eritoran 
(n=9) 
Control 
(n=10) 
AngII 
(n=10) 
SBP 
(mmHg) 106±5 152±12* 133±6* 157±12* 108±8 151±9* 
Total 
cholesterol 
(mg/dL) 
389±31 395±59 370±25 363±35 305±33 386±43 
Body 
weight (g) 29.1±1.1 30.2±1.5 28.5±1.0 29.0±1.2 29.5±1.4 30.1±1.0 
SBP was measured using a tail-cuff system. Total cholesterol and body weight were determined 
at the end of the study. All results are expressed as mean±SEM. *P<0.05 compared with control. 
 
Supplemental Table III 
Sequences of primers used for qPCR analysis 
Genes Forward Primer Reverse Primer 
TLR4 5’-tggctggtttacacatccatcggt-3’ 5’-tggcaccattgaagctgaggtcta-3’ 
iNOS 5’-gagacgcacaggcagagg-3’ 5’-caggcacacgcaatgatgg-3’ 
Ym-1 5’-cagaaccgtcagacattcatta-3’ 5’-atggtccttccagtaggtaata-3’ 
GAPDH 5’-tcaacggcacagtcaagg-3’ 5’-actccacgacatactcagc-3’ 
        
 
 
 
 
 
 
 
Supplemental Figure 1
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Figure S1 Representative aortas from control, AngII, and
AngII+S3I-201 treated ApoE-/- mice.
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Figure S2 AngII stimulates STAT3 phosphorylation in BMDMs
from ApoE-/- mice in a dose-dependent manner. BMDMs were
starved in DMEM for 8 hours followed by treatment with the
indicated concentrations of AngII for 16h. A. Western blot
analysis of pSTAT3 and tSTAT3. B. Densitometric analysis of
data in A normalized to GAPDH (*P<0.05 vs. control).
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Supplemental Figure 3
Figure S3 AngII stimulates STAT3 phosphorylation in VSMCs
from ApoE-/- mice. Furthermore, Ang II stimulation of MMP2
secretion in VSMCs is dependent on pSTAT3. (A) pSTAT3 and
tSTAT3 determined by western blot analysis of cell
homogenates and MMP2 in the growth medium were
determined by zymography. B. Densitometric analysis of data in
A normalized to GAPDH (*P<0.05, compared to control,
#P<0.05, compared to AngII, n=4).
pSTAT3
tSTAT3
GAPDH
S3I-201 (100µM) - - +
AngII (0.5 µM) - + +
MMP2
*
#
Supplemental Figure 4
Figure S4 Gating schema for flow cytometric identification of M1/M2
macrophages in aortic digests. Total cells were first gated by forward
and side scatter to distinguish lymphocytes in aortic digests. Cells
were further gated as shown, for CD11b+/lin- cells. M1 cells were
identified as CD11c+/MHC class II hi (left lower panel) while M2
macrophages were identified as CD206+ F4/80 hi (right lower panel).
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Figure S5 AngII treatment increases levels of TLR4 in BMDMs
from ApoE-/- mice in a dose-dependent manner. BMDMs were
starved in DMEM for 8 hours followed by treatment with the
indicated concentrations of AngII for 16h. (A) Western blot
analysis of TLR4 expression, (B) Densitometry scanning of data
in A normalized to GAPDH (*P<0.05, **P<0.01 vs. control).
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Supplemental Figure 6
Figure S6 TLR4 knockout attenuates AngII-induced wall thickness
in ApoE-/- mice
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Supplemental Figure 7
Figure S7 TLR4 knockout attenuates AngII-induced STAT3
phosphorylation and MMP2 activity. (A) pSTAT3 and tSTAT3
determined by western blot analysis of cell homogenates and
MMP2 in the growth medium were determined by zymography.
B. Densitometric analysis of data in A normalized to GAPDH
(**P< 0.01, compared to control, n=4).
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